OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
OncClub: Join the Chat on Trending Trials in CancerIn-person and virtual events just for HCPsLive Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer Register to join us LIVE in Chicago for Giants of Cancer Care®Subscribe to our eNewsletter for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
News Network
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • OncClub: Join the Chat on Trending Trials in Cancer
  • In-person and virtual events just for HCPs
  • Live Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer
  • Register to join us LIVE in Chicago for Giants of Cancer Care®
  • Subscribe to our eNewsletter for breaking news and curated content
SpecialtySee All >
  • Breast Cancer
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Rajat Bannerji, MD, PhD

  1. home

Articles

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

January 6th 2021

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma

April 23rd 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).

Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL

January 31st 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).